目的 探討金水寶膠囊聯(lián)合阿魏酸哌嗪治療慢性腎小球腎炎的臨床療效。方法 選取2021年7月—2023年7月眉山市人民醫(yī)院收治的148例慢性腎小球腎炎患者，采用隨機數(shù)字表法將148例慢性腎小球腎炎患者分為對照組（74例）和治療組（74例）。對照組患者口服阿魏酸哌嗪片，100 mg/次，3次/d。治療組患者在對照組的治療基礎(chǔ)上口服金水寶膠囊，6粒/次，3次/d。兩組均連續(xù)治療3個月。觀察兩組患者的療效和中醫(yī)癥狀改善時間，比較兩組治療前后血液高凝狀態(tài)指標、腎功能指標。結(jié)果 治療后，治療組的總有效率是94.59%，顯著高于對照組的83.78%（P＜0.05）。與對照組比較，治療組疲倦乏力、顏面浮腫、腰脊酸痛改善時間更短（P＜0.05）。治療3個月后，兩組纖維蛋白原、D-二聚體、血栓素B2（TXB2）水平均較同組治療前顯著降低（P＜0.05）；與對照組比較，治療3個月后治療組患者纖維蛋白原、D-二聚體、TXB2水平更低（P＜0.05）。治療后，兩組胱抑素C（CysC）、視黃醇結(jié)合蛋白（RBP）、尿素氮、肌酐水平均降低，而腎小球濾過率（eGFR）水平升高（P＜0.05）；與對照組比較，治療后治療組患者CysC、RBP、尿素氮、肌酐水平更低，eGFR水平更高（P＜0.05）。結(jié)論 金水寶膠囊聯(lián)合阿魏酸哌嗪治療慢性腎小球腎炎可獲得較為理想的治療效果，對患者血液高凝狀態(tài)以及腎功能均有明顯的改善作用，且無明顯不良反應(yīng)，安全性較高。

Objective To explore the therapeutic effect of Jinshuibao Capsules combined with piperazine ferulate in treatment of chronic glomerulonephritis. Methods A total of 148 patients with chronic glomerulonephritis admitted to Meishan City People’s Hospital from July 2021 to July 2023 were selected, and 148 patients with chronic glomerulonephritis were divided into control group (74 cases) and treatment group (74 cases) by random number table method. Patients in the control group were po administered with Piperazine Ferulate Tablets, 100 mg/time, three times daily. Patients in the treatment group were po administered with Jinshuibao Capsules on the basis of the control group, 6 grains/time, three times daily. Both groups were treated continuously for 3 months. The curative effect and the improvement time of TCM symptoms in two groups were observed, and the indexes of blood hypercoagulability and renal function before and after treatment were compared. Results After treatment, the total effective rate of the treatment group was 94.59%, which was significantly higher than that of the control group (83.78%, P < 0.05). Compared with the control group, the improvement time of fatigue, facial edema and lumbar soreness in the treatment group was shorter (P < 0.05). After 3 months of treatment, the levels of fibrinogen, D-dimer, and thromboxane B2 (TXB2) in 2 groups were significantly decreased compared with before treatment (P < 0.05). Compared with the control group, the levels of fibrinogen, D-dimer, and TXB2 in treatment group were lower after 3 months of treatment (P < 0.05). After treatment, the levels of cystatin C (CysC), retinol-binding protein (RBP), urea nitrogen and creatinine were decreased in both groups, but the levels of glomerular filtration rate (eGFR) were increased (P < 0.05). Compared with the control group, the levels of CysC, RBP, urea nitrogen, and creatinine in treatment group were lower after treatment, and the levels of eGFR were higher (P < 0.05). Conclusion Jinshuibao Capsules combined with piperazine ferulate achieves ideal therapeutic effects in treatment of chronic glomerulonephritis, and has a significant improvement effect on blood hypercoagulability and renal function in patients, and there are no significant adverse reactions with high safety.

R983

四川省科技計劃項目（19YYJC0256）